CompletedPhase 2NCT00086125
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
Studying Myelodysplastic/myeloproliferative disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Frank Haluska, M.D., Ph.D.Ariad Pharmaceuticals
- Intervention
- ridaforolimus(drug)
- Enrollment
- 57 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2004 – 2006
Study locations (8)
- University of Chicago Hospitals, Section of Hematology/Oncology, Chicago, Illinois, United States
- Washington University School of Medicine, Siteman Cancer Center, 4921 Parkview Place, St Louis, Missouri, United States
- The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- New York Presbyterian Hospital, Weill College of Cornell University, New York, New York, United States
- Morris Cancer Center - Duke University Medical Center, Adult Bone Marrow Transplant Clinic, Durham, North Carolina, United States
- Gabrail Cancer Center, Canton, Ohio, United States
- Jeane's Hospital of TUHS, Philadelphia, Pennsylvania, United States
- MD Anderson Cancer Center, Houston, Texas, United States
Collaborators
Ariad Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00086125 on ClinicalTrials.govOther trials for Myelodysplastic/myeloproliferative disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT05564390MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06532084Sorafenib Relapase Prophylaxis After HCT With PTBCy RegimenSt. Petersburg State Pavlov Medical University
- RECRUITINGPHASE2NCT05788679A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDSKarolinska University Hospital
- RECRUITINGPHASE2NCT04493164CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center
See all trials for Myelodysplastic/myeloproliferative disease →